Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216952 · ClinicalTrials.gov registry record · Phase 2
Ulipristal Acetate for Use in Early Pregnancy Loss
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05216952: Completed Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
NCT05216952 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216952, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, additional interventions needed, side effects, adverse events and patient acceptability.
Primary Outcome
Measured as number of participants enrolled in study divided by number of patients screened for participation in study
Interventions
- DRUG Ulipristal Acetate Tablets
- DRUG Misoprostol Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2023-04-30 |
| Phase | Phase 2 |
What the finished NCT05216952 record still lists
NCT05216952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Ulipristal Acetate Tablets is the first listed.
NCT05216952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05216952 about?
NCT05216952 is a clinical study titled "Ulipristal Acetate for Use in Early Pregnancy Loss". The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, a...
What is the current status of trial NCT05216952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-05-11. Estimated completion is 2023-04-30.
What interventions are being tested in trial NCT05216952?
The interventions under investigation include: Ulipristal Acetate Tablets (DRUG), Misoprostol Pill (DRUG).
Who is sponsoring clinical trial NCT05216952?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05216952's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI